Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Trading Up 2.8 %

Shares of BPTH opened at $1.10 on Wednesday. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $1.81. Bio-Path has a 52-week low of $0.85 and a 52-week high of $14.42.

Bio-Path (NASDAQ:BPTH) last posted its earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the company earned ($10.60) EPS. As a group, research analysts anticipate that Bio-Path will post -6.2 EPS for the current year.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent SEC filing. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.